Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...

Most policies still exclude weight-loss medications under general exclusions unless they are part of the treatment of a ...

A WOMAN has revealed how shedding a whopping 8st completely transformed her life but also landed her in a major surgery. The weight loss warrior, Em, has been documenting her transformation on her ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...

Newly published research claims those taking GLP-1 jabs are at a 37 percent lower risk of dementia than those on the anti-diabetic medication.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

New research published Tuesday concludes that the rising rate of extreme childhood obesity—well above the usual BMI ...

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...